The adjustment for age and BMI (model 1) or for the baseline use of some specific glucose-lowering agents, such as glucagon-like peptide 1 (GLP-1) receptor agonists (model 2), sodium-glucose cotransporter-2 (SGLT2) inhibitors (model 3) or pioglitazone (model 4) that might favourably affect NAFLD and liver fibrosis did not weaken the strength of this association. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.